- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
Increased risk of hepatocellular carcinoma in chronic hepatitis B patients with transient elastography–defined subclinical cirrhosis
Mi Na Kim1, Seung Up Kim1,2,*, Beom Kyung Kim1,2, Jun Yong Park1,2, Do Young Kim1,2, Sang Hoon Ahn1,2,5, Ki Jun Song3, Young Nyun Park4 andKwang-Hyub Han1,2,5,*
Article first published online: 20 MAR 2015
DOI: 10.1002/hep.27735
© 2015 by the American Association for the Study of Liver Diseases
Issue
Hepatology
Hepatology
Volume 61, Issue 6, pages 1851–1859, June 2015
Article has an altmetric score of 6
1 Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
2 Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea
3 Department of Biostatistics, Yonsei University College of Medicine, Seoul, Korea
4 Department of Pathology, Yonsei University College of Medicine, Seoul, Korea
5 Brain Korea 21 Project for Medical Science, Seoul, Korea
*Address reprint requests to: Seung Up Kim, M.D., Ph.D., Department of Internal Medicine, Yonsei University College of Medicine, 250 Seongsanno, Seodaemun-gu, Seoul 120-752, Korea. E-mail: [email protected]; fax: +82-2-362-6884 or Kwang-Hyub Han, M.D., Department of Internal Medicine, Yonsei University College of Medicine, 250 Seongsanno, Seodaemun-gu, Seoul 120-752, Korea. E-mail: [email protected]; fax: +82-2-362-6884.
Potential conflict of interest: Nothing to report.
This study was supported by a grant of the Korea Healthcare technology R&D Project, Ministry of Health and Welfare, Republic of Korea (HI10C2020). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Early detection of liver cirrhosis in its subclinical stage is of paramount importance to identify high-risk individuals for developing hepatocellular carcinoma (HCC). This study investigated whether transient elastography (TE) can identify patients with subclinical cirrhosis (SCC) who are at increased risk of developing HCC among chronic hepatitis B (CHB) patients without clinical evidence of cirrhosis. A total of 2,876 CHB patients without clinical cirrhosis who received TE examinations between April 2006 and December 2012 were enrolled in this prospective study. SCC was defined as a nonclinical cirrhosis, but with a liver stiffness (LS) value ≥13 kilopascals (kPa). Mean age of the study population was 46.1 years, and male gender was predominant (n = 1,775; 61.7%). Mean LS value was 7.9 kPa, and SCC was identified in 285 (9.9%) patients. During the median follow-up period of 48.9 months (range, 6.6-96.2), HCC developed in 16 patients (13.3 per 1,000 person-years) in the SCC group and 36 (3.4 per 1,000 person-years) in the non-SCC group. Cumulative incidence rate of HCC in the SCC group was significantly higher than that in the non-SCC group (P < 0.001, log-rank test). On multivariate analysis, SCC was independently associated with a risk of developing HCC, regardless of antiviral therapy (without antiviral therapy: hazard ratio [HR]: 4.680; 95% confidence interval [CI]: 1.187-18.441; P = 0.027; with antiviral therapy: HR, 3.344; 95% CI: 1.526-7.328; P = 0.003). Conclusion: TE can identify CHB patients with SCC who are at increased risk of developing HCC, even when cirrhosis is not clinically apparent. (Hepatology 2015;61:1851-1859)
|
|